Conceptus Inc., of San Carlos, Calif., appointed Charles Carignan vice president of clinical research and medical affairs.

Cyclacel Ltd., of Dundee, Scotland, appointed Robert Jackson executive director, research and development and also placed him on its board.

Dendreon Corp., of Seattle, promoted Reiner Laus to vice president, research.

DNA Sciences Inc., of Fremont, Calif., appointed Christopher Burrow director of medicine.

Entelos Inc., of Menlo Park, Calif., appointed Alan Blazei chief financial officer and Michael French vice president of strategic alliances.

Genomics Collaborative Inc., of Cambridge, Mass., appointed Spencer Wells director of population genetics.

HTS Biosystems Inc., of Hopkinton, Mass., added Joseph Ciffolillo and Larry Gold to its board.

Hypnion Inc., of Worcester, Mass., appointed Anita Hoffer vice president, business development.

ICN Pharmaceuticals Inc., of Costa Mesa, Calif., elected Ray Irani and Rosemary Tomich to its board.

Keryx Biopharmaceuticals Inc., of Jerusalem and Boston, appointed Wilson Totten and Malcolm Hoenlein to its board.

Matritech Inc., of Newton, Mass., elected Judith Kurland to its board.

Micrologix Biotech Inc., of Vancouver, British Columbia, appointed Kenneth Galbraith to its board.

MitoKor, of San Diego, appointed Ronald Deane chief business officer, Neil Howell vice president of research, Craig Johnson chief financial officer and Andrew Milner general manager of MitoKor's Australian subsidiary, Mimotopes.

OraSure Technologies Inc., of Bethlehem, Pa., appointed Richard Hooper chief financial officer.

OXIS International Inc., of Portland, Ore., appointed Peter Taussig to its board.

Palatin Technologies Inc., of Princeton, N.J., appointed Zola Horovitz to its board.

Phenome Sciences Inc., of Boston, added Georges Haas to its pharmaceutical advisory board.